PROSPECTS FOR THE USE OF PLATINUM DRUGS

Abstract

The article provides a summary of the biological effects and existing indications for the use of registered platinum compounds. Cisplatin continues to be used to treat a wide range of malignancies, the main ones being lung (49%), testicular (2%), ovarian (7%), uterine cancer (13%), head and neck tumors (16%), and bladder cancer (13%). The results of an analysis of the global market for these drugs and a forecast until 2026, as well as the Russian market for 2022, are presented. The prospects for the development and registration of new drugs and new promising combinations involving drugs from this group are described. Analysis of recommendations from the professional oncology community indicates continued widespread use of existing platinum drugs. There has been a trend towards an increase in global sales, largely due to their increase in the Asia-Pacific region, countries of Central Asia and Africa. On the Russian market, whose capacity is 1.3% and 1.9% of sales of all anticancer drugs in value and volume terms, domestic manufacturers are satisfactorily represented. New promising treatment regimens are being developed, including those that include proprietary drugs (primarily PARB inhibitors); There remains interest in the development of innovative platinum drugs. The summarized information was obtained from official sources of the State Register of Medicines of the Ministry of Health of Russia, the Electronic Rubricator of Clinical Recommendations and Clinical Guidelines and orders on Standards of Medical Care prepared on their basis, and the drug sales database of the marketing agency DSM Group.